SingVaSC, Singapore Vascular Surgical Collaborative, Singapore.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
J Vasc Access. 2024 Jan;25(1):14-26. doi: 10.1177/11297298221095320. Epub 2022 May 7.
Central venous occlusive disease (CVOD) is a complication that can occur in patients with end-stage renal disease who are receiving hemodialysis. When CVOD develops, patients often require multiple re-interventions to maintain their dialysis access. CVOD can be treated by various strategies such as balloon angioplasty, stenting, lower limb or extra-anatomical grafts, hybrid grafts or surgical bypasses such as right atrial (RA). In this systematic review, we aim to evaluate the indications, technical aspects, and outcomes after RA bypass grafting for the treatment of CVOD in hemodialysis patients.
A systematic and comprehensive literature search was conducted using various electronic databases. We included articles that reported described and reported outcomes of RA bypass grafting for the treatment of CVOD in hemodialysis patients. A narrative review of the indications and technical aspects of RA bypass grafting was performed. We also pooled and reported the primary patency, secondary patency, postoperative complications, and 30-day mortality of RA bypass grafting.
A total of 21 studies with 55 patients who underwent RA bypass grafting were included in our systematic review. Follow-up period ranged from 0.5 to 84 months. The mean pooled primary patency and secondary patency of RA bypass grafting were 8.1 ± 4.9 and 21.7 ± 20.1 months, respectively. The incidence of early postoperative complications such as surgical site infection, bleeding, and access thrombosis was 0%, 4%, and 4%, respectively. The overall 30-day mortality was 4%.
This systematic review summarizes the patient characteristics, technical features and outcomes of RA bypass grafting in the treatment of hemodialysis-related CVOD. RA bypass grafting may be a viable last-resort option when less invasive or conventional treatment options have been exhausted.
中心静脉闭塞性疾病(CVOD)是接受血液透析的终末期肾病患者可能发生的并发症。当 CVOD 发生时,患者通常需要多次再介入以维持其透析通路。CVOD 可以通过各种策略治疗,例如球囊血管成形术、支架置入、下肢或体外解剖移植物、杂交移植物或外科旁路,如右心房(RA)。在这项系统评价中,我们旨在评估 RA 旁路移植术治疗血液透析患者 CVOD 的适应证、技术方面和结果。
我们使用各种电子数据库进行了系统和全面的文献检索。我们纳入了描述和报告 RA 旁路移植术治疗血液透析患者 CVOD 的结果的文章。我们对 RA 旁路移植术的适应证和技术方面进行了叙述性综述。我们还汇总并报告了 RA 旁路移植术的主要通畅率、次要通畅率、术后并发症和 30 天死亡率。
我们的系统评价共纳入了 21 项研究,共 55 例接受 RA 旁路移植术的患者。随访时间从 0.5 到 84 个月不等。RA 旁路移植术的平均主要通畅率和次要通畅率分别为 8.1 ± 4.9 和 21.7 ± 20.1 个月。早期术后并发症(如手术部位感染、出血和通路血栓形成)的发生率分别为 0%、4%和 4%。总的 30 天死亡率为 4%。
本系统评价总结了 RA 旁路移植术治疗血液透析相关 CVOD 的患者特征、技术特点和结果。当较不侵入性或常规治疗方案已经用尽时,RA 旁路移植术可能是一种可行的最后手段。